Patients with chronic myeloid leukemia (CML) in accelerated phase may obtain less clinical benefit with first-line imatinib therapy compared with those with CML in chronic phase, according to a study presented at the 2016 Society of Hematologic Oncology Annual Meeting.1
There are limited data on the long-term outcome of patients with CML in accelerated phase versus chronic phase treated with imatinib in the first-line setting. Researchers compared long-term outcomes of these patients at their institution in Mexico City, Mexico.
Investigators analyzed data from 40 patients in chronic phase and 35 in accelerated phase who received imatinib 600 mg and 400 mg orally daily, respectively. Median age at the time of presentation was 44 years for patients in chronic phase and 36 years for those in accelerated phase.
Continue Reading
The median time to reach complete hematologic response was 1 month in chronic phase and 3 months in accelerated phase; the median time to achieve complete cytogenetic response was 8 months and 12 months, respectively. More than half of patients in accelerated phase did not achieve a response to imatinib.
Median duration of response significantly different between the 2 groups, with responses lasting a median of 73 months in patients with CML in chronic phase versus 30 months in those in accelerated phase (P < .0001).
RELATED: Higher EUTOS Risk Scores Linked With Delayed Response Rate in CML
At a median follow-up of 120 months, median overall survival was 150 months among patients in chronic phase, and 70 months among those in accelerated phase (P ≤ .001); median disease-free survival was 73 and 30 months, respectively.
Reference
- Vicente-Hernandez B, Hurtado-Monroy R, Sarre-Alvarez D, et al. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia Philadelphia + (CML-PH+) in accelerated phase (AP), comparison with chronic phase: A long term retrospective study. Poster presented at: 2016 Society of Hematologic Oncology Annual Meeting; September 7-10, 2016; Houston, TX.
